Why Zimmer Biomet ( ZBH ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - BioMarin Pharmaceutical ( NASDAQ:BMRN ) , Duolingo ( NASDAQ:DUOL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.
Zimmer Biomet Stock Falls As Weakness In Latin America And Certain EU Markets Impact Organic Growth Forecast - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) reported third-quarter adjusted earnings of $1.90 per share, up 9.2% year over year, beating the Street estimates of $1.87.
Zimmer Biomet ( ZBH ) Q3 Earnings Surpass Estimates
Zimmer (ZBH) delivered earnings and revenue surprises of +1.06% and -0.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
P/E Ratio Insights for Zimmer Biomet Holdings - Zimmer Biomet Holdings ( NYSE:ZBH )
In the current market session, Zimmer Biomet Holdings Inc. ( NYSE:ZBH ) share price is at $99.04, after a 0.84% decrease. Over the past month, the stock increased by 0.83%, but over the past year, it actually decreased by 9.34%.
What Does the Market Think About Zimmer Biomet Holdings Inc? - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings Inc's ( NYSE:ZBH ) short interest as a percent of float has risen 5.09% since its last report. According to exchange reported data, there are now 7.14 million shares sold short, which is 4.13% of all regular shares that are available for trading.
EIGHTH ANNUAL HISPANIC LEADERSHIP SUMMIT CONVENES 300 LEADERS IN NYC TO STRENGTHEN THE BUSINESS CASE FOR LATINOS
300 top Latino leaders and allies united at Civic Hall and the United Nations to drive alignment, trust, and strategic action for Latino leadership. Data from the 2025 Hispanic Sentiment Study revealed rising Latino confidence.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?
GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.
Will Zimmer ( ZBH ) Beat Estimates Again in Its Next Earnings Report?
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership
ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.
Will ISRG's dV5 Lend Momentum to Top Line During Q3 Earnings?
Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.
Zimmer Biomet to Report Q3 Earnings: Here's What to Expect
ZBH's Q3 results on Nov. 5 may show solid gains, driven by hip, knee, and S.E.T. segment growth and recent product approvals.
QSM Asset Management Dumps 36,000 Whirlpool ( WHR ) Shares in Q3 2025
QSM Asset Management Ltd disclosed the sale of 35,844 Whirlpool Corporation ( NYSE:WHR ) shares in its SEC filing for the period ended Q3 2025. This was an estimated $3.3 million trade based on the average quarterly price for Q3 2025.According to a filing with the U.S.
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market
On Thursday, QSM Asset Management disclosed a significant buy of Pfizer ( NYSE:PFE ) , adding shares worth an estimated $6.8 million in the third quarter.QSM Asset Management increased its position in Pfizer, adding 276,899 shares in the third quarter of 2025, according to a filing with the ...
Deal Dispatch: Confluent Considers Sale, Rothschild Exits The Economist, CVS Feels The Pain - Citigroup ( NYSE:C ) , Confluent ( NASDAQ:CFLT )
Confluent Inc. ( NASDAQ:CFLT ) , a California-based data streaming company, is exploring a potential sale after drawing interest from several private equity firms and tech companies. According to Reuters, the company has engaged an investment bank to advise on the early-stage process.
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.
Are Investors Undervaluing Zimmer Biomet ( ZBH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7
Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer - Beauty Health ( NASDAQ:SKIN )
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth
Looking Into Zimmer Biomet Holdings Inc's Recent Short Interest - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings Inc's ( NYSE:ZBH ) short interest as a percent of float has risen 13.1% since its last report. According to exchange reported data, there are now 6.57 million shares sold short, which is 3.8% of all regular shares that are available for trading.
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet ( ZBH Quick QuoteZBH - ) and EssilorLuxottica Unsponsored ADR ( ESLOY Quick QuoteESLOY - ) . But which of these two companies is the best option for those looking for undervalued stocks?
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
ISRG and ZBH both push robotics forward, but valuation and Zacks Rank tilt near-term upside toward Zimmer Biomet. Which one offers a better bet?
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
All You Need to Know About Zimmer ( ZBH ) Rating Upgrade to Buy
Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Zimmer Biomet ( ZBH ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Insider Decision: Sang Yi Offloads $124K Worth Of Zimmer Biomet Holdings Stock - Zimmer Biomet Holdings ( NYSE:ZBH )
Sang Yi, Group President at Zimmer Biomet Holdings ZBH, disclosed an insider sell on September 15, according to a recent SEC filing. What Happened: Yi's decision to sell 1,200 shares of Zimmer Biomet Holdings was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on ...
Why Zimmer Biomet ( ZBH ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Phibro Animal Health ( PAHC ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Mid-Cap Value Mutual Funds to Buy Amid Volatile Market Conditions
Amid market volatility, TGVOX, VASVX and TRMCX stand out with strong returns, low costs and exposure to growth-driven mid-cap value stocks.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Investors Undervaluing Smith & Nephew SNATS ( SNN ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet ( ZBH Quick QuoteZBH - ) and EssilorLuxottica Unsponsored ADR ( ESLOY Quick QuoteESLOY - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Stryker's Robotics and Global Gains Offset by Macro Concerns
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking Into Zimmer Biomet Holdings's Recent Short Interest - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings's ZBH short percent of float has fallen 19.29% since its last report. The company recently reported that it has 5.93 million shares sold short, which is 3.43% of all regular shares that are available for trading.
NeuroOne Q3 Revenue Jumps 105 Percent
NeuroOne Medical Technologies ( NASDAQ:NMTC ) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising to 53.9% from 34.1% in the third quarter of fiscal year 2024.
NeuroOne ( NMTC ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Aug. 14, 2025 at 8:30 a.m. ETChief Executive Officer - David A. RosaContinue reading ...
NeuroOne Revenue Jumps 105 Percent in Q3
NeuroOne Medical Technologies ( NASDAQ:NMTC ) , a med-tech company specializing in advanced thin film electrode and ablation systems for neurological disorders, reported Q3 FY2025 results on August 14, 2025. The earnings release showcased a material improvement in profitability, with earnings per ...
Why Zimmer Biomet ( ZBH ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
Zimmer Biomet Flexes Strong Q2, Raises 2025 Outlook - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Q2 EPS rises 3% to $2.07, beating the $1.99 estimate; sales reaches $2.08 billion, topping the consensus. 2025 EPS guidance raises to $8.10-$8.30 vs. $7.90-$8.10 prior; revenue growth forecast narrows to 6.7%-7.7% The market's back, and these 3 income stocks are thriving.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates. full-year EPS guidance raised on strong segment growth.
Zimmer Biomet ( ZBH ) Q2 Revenue Jumps 7%
Zimmer Biomet ( NYSE:ZBH ) , an orthopedic medical technology company, reported its earnings on August 7, 2025. The company announced GAAP revenue of $2.077 billion, beating analyst estimates of $2.057 billion. Adjusted earnings per share ( EPS ) , a profitability metric that excludes certain ...
